Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors

Daugaard, 2014, Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort, J Clin Oncol, 32, 3817, 10.1200/JCO.2013.53.5831 Kollmannsberger, 2015, Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance, J Clin Oncol, 33, 51, 10.1200/JCO.2014.56.2116 Nayan, 2016, The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours, Can Urol Assoc J, 10, 204, 10.5489/cuaj.3513 Albers, 2015, Guidelines on testicular cancer: 2015 update, Eur Urol, 68, 1054, 10.1016/j.eururo.2015.07.044 Motzer, 2015, Testicular cancer, version 2.2015, J Natl Compr Cancer Netw, 13, 772, 10.6004/jnccn.2015.0092 Vesprini, 2012, Utility of serum tumor markers during surveillance for stage I seminoma, Cancer, 118, 5245, 10.1002/cncr.27539 Chung, 2019, Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours, Eur Urol Oncol, 2, 437, 10.1016/j.euo.2018.08.031 Hamilton, 2019, Treatment of relapse of clinical stage I nonseminomatous germ cell tumors on surveillance, J Clin Oncol, 37, 1919, 10.1200/JCO.18.01250 Sharir, 1999, Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol, J Urol, 161, 472, 10.1016/S0022-5347(01)61926-8 Sturgeon, 1992, Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors, J Clin Oncol, 10, 564, 10.1200/JCO.1992.10.4.564 Sturgeon, 2011, Non-risk-adapted surveillance in clinical stage i nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience, Eur Urol, 59, 556, 10.1016/j.eururo.2010.12.010 Thomas, 1989, A study of post-orchiectomy surveillance in stage I testicular seminoma, J Urol, 142, 313, 10.1016/S0022-5347(17)38742-6 Warde, 1993, Results of a policy of surveillance in stage I testicular seminoma, Int J Radiat Oncol, 27, 11, 10.1016/0360-3016(93)90415-R Chung, 2002, Surveillance in stage I testicular seminoma—risk of late relapse, Can J Urol, 9, 1637 Leung, 2013, Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy, BJU Int, 112, 1088, 10.1111/bju.12330 Hosni, 2016, Clinical characteristics and outcomes of late relapse in stage I testicular seminoma, Clin Oncol, 28, 648, 10.1016/j.clon.2016.06.001 O’Malley, 2010, Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance, Eur Radiol, 20, 1624, 10.1007/s00330-009-1710-1 Pierorazio, 2018, Non–risk-adapted surveillance for stage I testicular cancer: critical review and summary, Eur Urol, 73, 899, 10.1016/j.eururo.2017.12.030 Gilligan, 2019, Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology, J Natl Compr Cancer Netw, 17, 1529, 10.6004/jnccn.2019.0058 Stephenson, 2019, Diagnosis and treatment of early stage testicular cancer: AUA guideline, J Urol, 202, 272, 10.1097/JU.0000000000000318 Laguna, 2001, EAU guidelines on testicular cancer, Eur Urol, 40, 102, 10.1159/000049759 Tolan, 2010, No role for routine chest radiography in stage I seminoma surveillance, Eur Urol, 57, 474, 10.1016/j.eururo.2009.06.029 Van As, 2008, Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse, Br J Cancer, 98, 1894, 10.1038/sj.bjc.6604280 Lieng, 2018, Recommendations for followup of stage I and II seminoma: the Princess Margaret Cancer Centre approach, J Can Urol Assoc, 12, 59, 10.5489/cuaj.4531 Joffe, 2021, Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, phase III, factorial trial (TRISST), J Clin Oncol, 39, 374, 10.1200/JCO.2021.39.6_suppl.374 Gilbert, 2019, Optimal management of high-risk stage I nonseminoma germ cell tumor: active intervention is the preferred option, Eur Urol Focus, 5, 704, 10.1016/j.euf.2019.09.009 Hamilton, 2019, Optimal management of high-risk stage I nonseminomatous germ cell tumor: surveillance is the preferred option, Eur Urol Focus, 5, 702, 10.1016/j.euf.2019.05.003 Lavi, 2020, Long-term testis cancer survivors in Canada—mortality risks in a large population-based cohort, Eur Urol Open Sci, 22, 54, 10.1016/j.euros.2020.10.005 Dieckmann, 2019, Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study, J Clin Oncol, 37, 1412, 10.1200/JCO.18.01480 Lobo, 2021, Utility of serum miR-371a-3p in predicting relapse on surveillance in patients with clinical stage I testicular germ cell cancer, Eur Urol Oncol, 4, 483, 10.1016/j.euo.2020.11.004